PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Gross profit growth of 100.00% while RVPH is zero. Bruce Berkowitz would see if minimal improvements could expand further.
-1.47%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.47%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.63%
EPS growth at 50-75% of RVPH's 3.85%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
2.63%
Diluted EPS growth at 50-75% of RVPH's 3.85%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
3.22%
Share reduction more than 1.5x RVPH's 10.63%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.22%
Diluted share reduction more than 1.5x RVPH's 10.64%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative OCF growth while RVPH is at 49.96%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-50.21%
Negative FCF growth while RVPH is at 49.96%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while RVPH stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.36%
Positive long-term OCF/share growth while RVPH is negative. John Neff would see a structural advantage in sustained cash generation.
62.52%
Positive OCF/share growth while RVPH is negative. John Neff might see a comparative advantage in operational cash viability.
-48.56%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
94.18%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
69.28%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
-24.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-50.75%
Negative equity/share CAGR over 10 years while RVPH stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-32.62%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-67.01%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-15.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.46%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
10.75%
R&D dropping or stable vs. RVPH's 22.81%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-21.32%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.